Novavax Shares Soar 130% on $1.4B Sanofi Deal

Novavax, a biotechnology company, experienced a staggering surge in its stock price, soaring over 130% in Friday’s early trading hours. This remarkable increase came on the heels of the company’s announcement of a monumental $1.4 billion deal with Sanofi, a global pharmaceutical giant. The agreement entails the commercialization of Novavax’s Covid-19 vaccine and the collaborative development of a new combination vaccine designed to protect against both influenza and Covid-19.

The surge in Novavax’s shares was substantial, with prices reaching $10.41 by 10:00 a.m. on Friday, marking a remarkable 132% increase from the previous day’s close. This surge built upon an earlier uptick in premarket trading, highlighting the market’s enthusiastic response to the news.

Under the terms of the agreement, Sanofi has secured the exclusive global rights to commercialize Novavax’s Covid-19 vaccine. Sanofi will make an upfront payment of $500 million to Novavax, with additional payments of up to $700 million contingent upon the achievement of certain milestones. Additionally, Novavax will receive royalties on sales of the vaccine.

In a strategic move, Sanofi will also acquire a stake of less than 5% in Novavax, solidifying the partnership between the two companies. Furthermore, Sanofi has been granted a sole license to develop and market a combination vaccine that includes Novavax’s Covid-19 vaccine and Sanofi’s own flu vaccine. This combination vaccine aims to provide comprehensive protection against both influenza and Covid-19.

As part of the deal, Novavax stands to gain additional milestone payments of up to $200 million for any vaccine developed by Sanofi under the agreement. This additional financial incentive underscores the potential long-term benefits of the collaboration for Novavax.

Looking ahead, Novavax is set to initiate a late-stage clinical trial of its combination vaccine targeting both Covid-19 and influenza. Additionally, the company plans to introduce a standalone flu vaccine later this year, further expanding its portfolio of immunization products.

Novavax’s CEO, John Jacobs, expressed optimism about the agreement, highlighting its significance for the company’s future. Jacobs emphasized that the deal strengthens Novavax’s financial position, alleviates concerns about its ability to sustain operations, and allows the company to focus on its core strengths.

The agreement with Sanofi is expected to significantly enhance Novavax’s prospects, particularly in light of the company’s recent financial challenges. In its first-quarter review, Novavax revised its 2024 sales forecast downward, citing challenges in the competitive landscape. Despite these challenges, the company remains optimistic about its future, buoyed by the promising partnership with Sanofi.